WO2010021692A1
(en)
|
2008-08-22 |
2010-02-25 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted single-stranded cleavage and targeted integration
|
US20110023147A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of prion disorder-related genes in animals
|
US20110023141A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved with parkinson's disease
|
US20110016546A1
(en)
*
|
2008-12-04 |
2011-01-20 |
Sigma-Aldrich Co. |
Porcine genome editing with zinc finger nucleases
|
US20110030072A1
(en)
*
|
2008-12-04 |
2011-02-03 |
Sigma-Aldrich Co. |
Genome editing of immunodeficiency genes in animals
|
US20110023139A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in cardiovascular disease
|
US20110023140A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Rabbit genome editing with zinc finger nucleases
|
US20110023150A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genome editing of genes associated with schizophrenia in animals
|
US20110023149A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in tumor suppression in animals
|
US20110023144A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in amyotrophyic lateral sclerosis disease
|
US20110023143A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of neurodevelopmental genes in animals
|
US20110023151A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genome editing of abc transporters
|
US20110023158A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Bovine genome editing with zinc finger nucleases
|
US20110023154A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Silkworm genome editing with zinc finger nucleases
|
US20110023152A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genome editing of cognition related genes in animals
|
US20110023153A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in alzheimer's disease
|
US20110023148A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genome editing of addiction-related genes in animals
|
US20110016539A1
(en)
*
|
2008-12-04 |
2011-01-20 |
Sigma-Aldrich Co. |
Genome editing of neurotransmission-related genes in animals
|
US20110023146A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in secretase-associated disorders
|
US20110023145A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in autism spectrum disorders
|
US20110016541A1
(en)
*
|
2008-12-04 |
2011-01-20 |
Sigma-Aldrich Co. |
Genome editing of sensory-related genes in animals
|
US20110016543A1
(en)
*
|
2008-12-04 |
2011-01-20 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in inflammation
|
US20110023156A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Feline genome editing with zinc finger nucleases
|
US20110016540A1
(en)
*
|
2008-12-04 |
2011-01-20 |
Sigma-Aldrich Co. |
Genome editing of genes associated with trinucleotide repeat expansion disorders in animals
|
US20130059388A1
(en)
*
|
2010-04-13 |
2013-03-07 |
Sigma-Aldrich Co., Llc |
Methods for generating endogenously tagged proteins
|
KR101880536B1
(ko)
*
|
2010-04-26 |
2018-07-23 |
상가모 테라퓨틱스, 인코포레이티드 |
아연 핑거 뉴클레아제를 사용하는 로사 좌위의 게놈 편집
|
KR20180121665A
(ko)
*
|
2010-07-23 |
2018-11-07 |
시그마-알드리치 컴퍼니., 엘엘씨 |
표적화 엔도뉴클레아제 및 단일-가닥 핵산을 사용하는 게놈 편집
|
US9057057B2
(en)
|
2010-07-27 |
2015-06-16 |
The Johns Hopkins University |
Obligate heterodimer variants of foki cleavage domain
|
WO2012018726A1
(en)
*
|
2010-08-02 |
2012-02-09 |
Cellectis Sa |
Method for increasing double-strand break-induced gene targeting
|
CA2823061A1
(en)
*
|
2010-12-29 |
2012-07-05 |
Dow Agrosciences Llc |
Data analysis of dna sequences
|
US10920242B2
(en)
|
2011-02-25 |
2021-02-16 |
Recombinetics, Inc. |
Non-meiotic allele introgression
|
CN103930550B
(zh)
*
|
2011-02-25 |
2017-02-15 |
重组股份有限公司 |
经遗传修饰的动物及其生成方法
|
US9187567B2
(en)
|
2011-05-18 |
2015-11-17 |
Parkinson's Institute |
Assay to determine LRRK2 activity in parkinson's disease
|
EP2737063B1
(en)
|
2011-07-25 |
2016-06-01 |
Sangamo BioSciences, Inc. |
Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
AU2012312260B2
(en)
|
2011-09-21 |
2017-08-31 |
Sangamo Therapeutics, Inc. |
Methods and compositions for regulation of transgene expression
|
US8895264B2
(en)
|
2011-10-27 |
2014-11-25 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the HPRT locus
|
JP6144691B2
(ja)
|
2011-11-16 |
2017-06-07 |
サンガモ セラピューティクス, インコーポレイテッド |
修飾されたdna結合タンパク質およびその使用
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
AU2013251558B2
(en)
|
2012-04-25 |
2019-01-03 |
Regeneron Pharmaceuticals, Inc. |
Nuclease-mediated targeting with large targeting vectors
|
EP2844754B1
(en)
|
2012-05-02 |
2018-10-24 |
Dow AgroSciences LLC |
Targeted modification of malate dehydrogenase
|
AU2013259647B2
(en)
|
2012-05-07 |
2018-11-08 |
Corteva Agriscience Llc |
Methods and compositions for nuclease-mediated targeted integration of transgenes
|
RS64622B1
(sr)
|
2012-05-25 |
2023-10-31 |
Univ California |
Metode i sastavi za modifikaciju ciljane dnk upravljenu pomoću rnk i za modulaciju transkripcije upravljanu rnk
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
CA2875618C
(en)
|
2012-07-11 |
2021-04-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for the treatment of lysosomal storage diseases
|
JP6329537B2
(ja)
|
2012-07-11 |
2018-05-23 |
サンガモ セラピューティクス, インコーポレイテッド |
生物学的薬剤の送達のための方法および組成物
|
CN104704110B
(zh)
|
2012-08-29 |
2018-06-01 |
桑格摩生物科学股份有限公司 |
用于治疗遗传性病状的方法和组合物
|
UA118090C2
(uk)
|
2012-09-07 |
2018-11-26 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
|
KR102147007B1
(ko)
|
2012-09-07 |
2020-08-21 |
다우 아그로사이언시즈 엘엘씨 |
Fad3 성능 유전자좌 및 표적화 파단을 유도할 수 있는 상응하는 표적 부위 특이적 결합 단백질
|
GB201216564D0
(en)
*
|
2012-09-17 |
2012-10-31 |
Univ Edinburgh |
Genetically edited animal
|
CA2886684C
(en)
|
2012-10-10 |
2023-09-19 |
Sangamo Biosciences, Inc. |
T cell modifying compounds and uses thereof
|
CA2892448A1
(en)
|
2012-12-05 |
2014-06-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of metabolic disorders
|
ES2757808T3
(es)
|
2012-12-06 |
2020-04-30 |
Sigma Aldrich Co Llc |
Modificación y regulación del genoma basada en CRISPR
|
JP6491113B2
(ja)
|
2013-02-25 |
2019-03-27 |
サンガモ セラピューティクス, インコーポレイテッド |
ヌクレアーゼ媒介性遺伝子破壊を増強するための方法および組成物
|
ES2786253T3
(es)
|
2013-03-14 |
2020-10-09 |
Immusoft Corp |
Métodos para la diferenciación y transducción in vitro de células b de memoria con vectores virales pseudotipados vsv-g
|
CN105980575A
(zh)
|
2013-03-14 |
2016-09-28 |
卡里布生物科学公司 |
以核酸为靶的核酸的组合物和方法
|
EP2975942B1
(en)
|
2013-03-21 |
2018-08-08 |
Sangamo Therapeutics, Inc. |
Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
|
EP3679785A3
(en)
|
2013-04-05 |
2020-09-16 |
Dow AgroSciences LLC |
Methods and compositions for integration of an exogenous sequence within the genome of plants
|
WO2014172458A1
(en)
*
|
2013-04-16 |
2014-10-23 |
University Of Washington Through Its Center For Commercialization |
Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering
|
CN111500630A
(zh)
|
2013-04-16 |
2020-08-07 |
瑞泽恩制药公司 |
大鼠基因组的靶向修饰
|
WO2014182700A1
(en)
|
2013-05-10 |
2014-11-13 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
AU2014265331B2
(en)
|
2013-05-15 |
2019-12-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a genetic condition
|
CA2920253A1
(en)
|
2013-08-02 |
2015-02-05 |
Enevolv, Inc. |
Processes and host cells for genome, pathway, and biomolecular engineering
|
DK3030682T3
(da)
|
2013-08-05 |
2020-09-14 |
Twist Bioscience Corp |
De novo synthesized gene libraries
|
EP3988654A1
(en)
|
2013-08-28 |
2022-04-27 |
Sangamo Therapeutics, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
ES2681622T3
(es)
*
|
2013-09-18 |
2018-09-14 |
Kymab Limited |
Métodos, células y organismos
|
US10117899B2
(en)
|
2013-10-17 |
2018-11-06 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
|
US9957526B2
(en)
|
2013-10-17 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
AU2014341934B2
(en)
|
2013-11-04 |
2017-12-07 |
Corteva Agriscience Llc |
Optimal soybean loci
|
US10233465B2
(en)
|
2013-11-04 |
2019-03-19 |
Dow Agrosciences Llc |
Optimal soybean loci
|
CA2928666C
(en)
|
2013-11-04 |
2023-05-23 |
Dow Agrosciences Llc |
Optimal maize loci for targeted genome modification
|
JP6649261B2
(ja)
|
2013-11-04 |
2020-02-19 |
ダウ アグロサイエンシィズ エルエルシー |
最適なトウモロコシ遺伝子座
|
EP3960856A1
(en)
|
2013-11-13 |
2022-03-02 |
Children's Medical Center Corporation |
Nuclease-mediated regulation of gene expression
|
DK3080274T3
(da)
|
2013-12-09 |
2020-08-31 |
Sangamo Therapeutics Inc |
Fremgangsmåder og sammensætninger til genom-manipulation
|
CN105980568B
(zh)
|
2013-12-11 |
2019-12-03 |
瑞泽恩制药公司 |
用于靶向修饰基因组的方法和组合物
|
US10774338B2
(en)
|
2014-01-16 |
2020-09-15 |
The Regents Of The University Of California |
Generation of heritable chimeric plant traits
|
EP3102673B1
(en)
|
2014-02-03 |
2020-04-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a beta thalessemia
|
EP3110454B1
(en)
|
2014-02-24 |
2020-11-18 |
Sangamo Therapeutics, Inc. |
Methods and compositions for nuclease-mediated targeted integration
|
CN106459894B
(zh)
|
2014-03-18 |
2020-02-18 |
桑格摩生物科学股份有限公司 |
用于调控锌指蛋白表达的方法和组合物
|
KR102417915B1
(ko)
|
2014-03-21 |
2022-07-07 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
뉴클레아제 없는 게놈 편집
|
WO2015164748A1
(en)
|
2014-04-24 |
2015-10-29 |
Sangamo Biosciences, Inc. |
Engineered transcription activator like effector (tale) proteins
|
EP3139966B1
(en)
|
2014-05-08 |
2020-11-18 |
Sangamo Therapeutics, Inc. |
Compositions for use in treating huntington's disease
|
WO2015175642A2
(en)
|
2014-05-13 |
2015-11-19 |
Sangamo Biosciences, Inc. |
Methods and compositions for prevention or treatment of a disease
|
WO2015188065A1
(en)
|
2014-06-05 |
2015-12-10 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease design
|
WO2016007604A1
(en)
|
2014-07-09 |
2016-01-14 |
Gen9, Inc. |
Compositions and methods for site-directed dna nicking and cleaving
|
US20170142942A1
(en)
|
2014-07-14 |
2017-05-25 |
Washington State University |
Nanos knock-out that ablates germline cells
|
WO2016014794A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
|
WO2016014837A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Gene editing for hiv gene therapy
|
WO2016019144A2
(en)
|
2014-07-30 |
2016-02-04 |
Sangamo Biosciences, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
PL3194570T3
(pl)
|
2014-09-16 |
2021-12-20 |
Sangamo Therapeutics, Inc. |
Sposoby i kompozycje do inżynierii genomowej w której pośredniczy nukleaza i korekty hematopoetycznych komórek macierzystych
|
DK3221457T3
(da)
|
2014-11-21 |
2019-06-03 |
Regeneron Pharma |
Fremgangsmåder og sammensætninger til targeteret genomisk modifikation ved anvendelse af parrede førings-rnaer
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
WO2016118726A2
(en)
|
2015-01-21 |
2016-07-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for identification of highly specific nucleases
|
US10669304B2
(en)
|
2015-02-04 |
2020-06-02 |
Twist Bioscience Corporation |
Methods and devices for de novo oligonucleic acid assembly
|
WO2016126987A1
(en)
|
2015-02-04 |
2016-08-11 |
Twist Bioscience Corporation |
Compositions and methods for synthetic gene assembly
|
WO2016172377A1
(en)
|
2015-04-21 |
2016-10-27 |
Twist Bioscience Corporation |
Devices and methods for oligonucleic acid library synthesis
|
US10179918B2
(en)
|
2015-05-07 |
2019-01-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for increasing transgene activity
|
EP3294896A1
(en)
|
2015-05-11 |
2018-03-21 |
Editas Medicine, Inc. |
Optimized crispr/cas9 systems and methods for gene editing in stem cells
|
JP6873917B2
(ja)
|
2015-05-12 |
2021-05-19 |
サンガモ セラピューティクス, インコーポレイテッド |
ヌクレアーゼ介在性遺伝子発現調節
|
CA2986262A1
(en)
|
2015-06-09 |
2016-12-15 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for improving transplantation
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
EP3322297A4
(en)
|
2015-07-13 |
2019-04-17 |
Sangamo Therapeutics, Inc. |
RELEASE METHOD AND COMPOSITIONS FOR NUCLEASE-DERIVED GENOMINE ENGINEERING
|
EP3325668B1
(en)
*
|
2015-07-23 |
2021-01-06 |
Mayo Foundation for Medical Education and Research |
Editing mitochondrial dna
|
PL3331355T3
(pl)
|
2015-08-06 |
2024-08-05 |
The Curators Of The University Of Missouri |
Zwierzęta z rodzaju świń odporne na wirusa zespołu rozrodczo- oddechowego świń (prrsv) i komórki mające zmodyfikowane geny cd163
|
CA2998169A1
(en)
|
2015-09-18 |
2017-03-23 |
Twist Bioscience Corporation |
Oligonucleic acid variant libraries and synthesis thereof
|
CN108698012A
(zh)
|
2015-09-22 |
2018-10-23 |
特韦斯特生物科学公司 |
用于核酸合成的柔性基底
|
CN108348576B
(zh)
|
2015-09-23 |
2022-01-11 |
桑格摩生物治疗股份有限公司 |
Htt阻抑物及其用途
|
AU2016326711B2
(en)
|
2015-09-24 |
2022-11-03 |
Editas Medicine, Inc. |
Use of exonucleases to improve CRISPR/Cas-mediated genome editing
|
WO2017053729A1
(en)
|
2015-09-25 |
2017-03-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nuclease-mediated genome editing of primary cells and enrichment thereof
|
AU2016343887B2
(en)
|
2015-10-28 |
2023-04-06 |
Sangamo Therapeutics, Inc. |
Liver-specific constructs, factor VIII expression cassettes and methods of use thereof
|
EP3380622A4
(en)
|
2015-11-23 |
2019-08-07 |
Sangamo Therapeutics, Inc. |
METHODS AND COMPOSITIONS FOR MODIFYING IMMUNITY
|
WO2017095958A1
(en)
|
2015-12-01 |
2017-06-08 |
Twist Bioscience Corporation |
Functionalized surfaces and preparation thereof
|
IL259935B2
(en)
|
2015-12-18 |
2023-03-01 |
Sangamo Therapeutics Inc |
Directed cleavage of cell mhc receptor
|
US11352631B2
(en)
|
2015-12-18 |
2022-06-07 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the T cell receptor
|
JP6930052B2
(ja)
|
2016-01-15 |
2021-09-01 |
サンガモ セラピューティクス, インコーポレイテッド |
神経性疾患の処置のための方法および組成物
|
EP3769775A3
(en)
|
2016-02-02 |
2021-03-17 |
Sangamo Therapeutics, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
WO2017165826A1
(en)
|
2016-03-25 |
2017-09-28 |
Editas Medicine, Inc. |
Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
|
WO2017180694A1
(en)
|
2016-04-13 |
2017-10-19 |
Editas Medicine, Inc. |
Cas9 fusion molecules gene editing systems, and methods of use thereof
|
US20180004537A1
(en)
|
2016-07-01 |
2018-01-04 |
Microsoft Technology Licensing, Llc |
Molecular State Machines
|
US10669558B2
(en)
|
2016-07-01 |
2020-06-02 |
Microsoft Technology Licensing, Llc |
Storage through iterative DNA editing
|
US11359234B2
(en)
|
2016-07-01 |
2022-06-14 |
Microsoft Technology Licensing, Llc |
Barcoding sequences for identification of gene expression
|
EP4053146A3
(en)
|
2016-08-15 |
2022-12-07 |
enEvolv, Inc. |
Molecule sensor systems
|
SG11201901563UA
(en)
|
2016-08-22 |
2019-03-28 |
Twist Bioscience Corp |
De novo synthesized nucleic acid libraries
|
KR20220145913A
(ko)
|
2016-08-24 |
2022-10-31 |
상가모 테라퓨틱스, 인코포레이티드 |
가공된 표적 특이적 뉴클레아제
|
KR102572759B1
(ko)
|
2016-08-24 |
2023-08-29 |
상가모 테라퓨틱스, 인코포레이티드 |
조작된 뉴클레아제를 이용하는 유전자 발현의 조절
|
EP3509645A4
(en)
|
2016-09-07 |
2020-06-17 |
Sangamo Therapeutics, Inc. |
MODULATION OF LIVER GENES
|
JP6871364B2
(ja)
|
2016-09-21 |
2021-05-12 |
ツイスト バイオサイエンス コーポレーション |
核酸に基づくデータ保存
|
CN110139873A
(zh)
|
2016-10-03 |
2019-08-16 |
朱诺治疗学股份有限公司 |
Hpv特异性结合分子
|
WO2018075736A1
(en)
|
2016-10-20 |
2018-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of fabry disease
|
WO2018081775A1
(en)
|
2016-10-31 |
2018-05-03 |
Sangamo Therapeutics, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
JP7292204B2
(ja)
|
2016-12-01 |
2023-06-16 |
サンガモ セラピューティクス, インコーポレイテッド |
タウモジュレーターならびにその送達のための方法および組成物
|
JP7416406B2
(ja)
|
2016-12-08 |
2024-01-17 |
ケース ウェスタン リザーブ ユニバーシティ |
機能的ミエリン産生を増進させるための方法および組成物
|
US10907274B2
(en)
|
2016-12-16 |
2021-02-02 |
Twist Bioscience Corporation |
Variant libraries of the immunological synapse and synthesis thereof
|
US12110545B2
(en)
|
2017-01-06 |
2024-10-08 |
Editas Medicine, Inc. |
Methods of assessing nuclease cleavage
|
CN108314736B
(zh)
*
|
2017-01-18 |
2021-08-31 |
李燕强 |
一种促进rna降解的方法
|
EP3586255A4
(en)
|
2017-02-22 |
2021-03-31 |
Twist Bioscience Corporation |
NUCLEIC ACID-BASED DATA STORAGE
|
US10894959B2
(en)
|
2017-03-15 |
2021-01-19 |
Twist Bioscience Corporation |
Variant libraries of the immunological synapse and synthesis thereof
|
US11499151B2
(en)
|
2017-04-28 |
2022-11-15 |
Editas Medicine, Inc. |
Methods and systems for analyzing guide RNA molecules
|
ES2981244T3
(es)
|
2017-04-28 |
2024-10-07 |
Acuitas Therapeutics Inc |
Novedosas formulaciones de nanopartículas de lípidos de carbonilo y lípidos para la administración de ácidos nucleicos
|
CN110869497A
(zh)
|
2017-05-03 |
2020-03-06 |
桑格摩生物治疗股份有限公司 |
修饰囊性纤维化跨膜传导调节蛋白(cftr)基因的方法和组合物
|
WO2018227114A1
(en)
|
2017-06-09 |
2018-12-13 |
Editas Medicine, Inc. |
Engineered cas9 nucleases
|
JP7169999B2
(ja)
|
2017-06-12 |
2022-11-11 |
ツイスト バイオサイエンス コーポレーション |
シームレス核酸アセンブリのための方法
|
WO2018231864A1
(en)
|
2017-06-12 |
2018-12-20 |
Twist Bioscience Corporation |
Methods for seamless nucleic acid assembly
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
EP3652312A1
(en)
|
2017-07-14 |
2020-05-20 |
Editas Medicine, Inc. |
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
|
KR20200047706A
(ko)
|
2017-09-11 |
2020-05-07 |
트위스트 바이오사이언스 코포레이션 |
Gpcr 결합 단백질 및 이의 합성 방법
|
MA50613A
(fr)
|
2017-10-03 |
2020-08-12 |
Editas Medicine Inc |
Molécules de liaison spécifique à l'hpv
|
JP7066840B2
(ja)
|
2017-10-20 |
2022-05-13 |
ツイスト バイオサイエンス コーポレーション |
ポリヌクレオチド合成のための加熱されたナノウェル
|
US11851679B2
(en)
|
2017-11-01 |
2023-12-26 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
JP2021502085A
(ja)
|
2017-11-09 |
2021-01-28 |
サンガモ セラピューティクス, インコーポレイテッド |
サイトカイン誘導性sh2含有タンパク質(cish)遺伝子の遺伝子改変
|
CA3088911A1
(en)
|
2018-01-04 |
2019-07-11 |
Twist Bioscience Corporation |
Dna-based storage device and method for synthesizing polynucleotides using the device
|
BR112020015488A2
(pt)
|
2018-02-08 |
2020-12-08 |
Sangamo Therapeutics, Inc. |
Nucleases alvo-específicas modificadas
|
AU2019233929A1
(en)
|
2018-03-16 |
2020-09-24 |
Immusoft Corporation |
B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength
|
WO2019183349A1
(en)
*
|
2018-03-21 |
2019-09-26 |
Sangamo Therapeutics, Inc. |
Genetic modification of mitochondrial genomes
|
JP2021520202A
(ja)
|
2018-04-05 |
2021-08-19 |
ジュノー セラピューティクス インコーポレイテッド |
組換え受容体を発現する細胞の作製方法および関連組成物
|
RU2020136054A
(ru)
|
2018-04-05 |
2022-05-06 |
Джуно Терапьютикс, Инк. |
Т-клетки, экспрессирующие рекомбинантный рецептор, соответствующие полинуклеотиды и способы
|
US11471489B2
(en)
|
2018-04-05 |
2022-10-18 |
Juno Therapeutics, Inc. |
T cell receptors and engineered cells expressing same
|
CA3100739A1
(en)
|
2018-05-18 |
2019-11-21 |
Twist Bioscience Corporation |
Polynucleotides, reagents, and methods for nucleic acid hybridization
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
SG11202101801RA
(en)
*
|
2018-08-23 |
2021-03-30 |
Sangamo Therapeutics Inc |
Engineered target specific base editors
|
KR20210060533A
(ko)
|
2018-09-18 |
2021-05-26 |
상가모 테라퓨틱스, 인코포레이티드 |
프로그램화된 세포 사멸 1 (pd1) 특이적 뉴클레아제
|
WO2020069029A1
(en)
|
2018-09-26 |
2020-04-02 |
Emendobio Inc. |
Novel crispr nucleases
|
JP7472121B2
(ja)
|
2018-10-18 |
2024-04-22 |
インテリア セラピューティクス,インコーポレーテッド |
アルブミン遺伝子座からの導入遺伝子発現のための組成物及び方法
|
JP2022505381A
(ja)
|
2018-10-18 |
2022-01-14 |
インテリア セラピューティクス,インコーポレーテッド |
アルファ1アンチトリプシン欠乏症を治療するための組成物及び方法
|
WO2020082041A1
(en)
|
2018-10-18 |
2020-04-23 |
Intellia Therapeutics, Inc. |
Nucleic acid constructs and methods of use
|
CA3116331A1
(en)
|
2018-10-18 |
2020-04-23 |
Intellia Therapeutics, Inc. |
Compositions and methods for expressing factor ix
|
EP3673920A1
(en)
|
2018-12-28 |
2020-07-01 |
Universität Wien |
Polyphenol-peptide conjugates for nuclear-targeted delivery
|
JP7523449B2
(ja)
|
2019-01-11 |
2024-07-26 |
アクイタス セラピューティクス インコーポレイテッド |
活性剤の脂質ナノ粒子送達のための脂質
|
WO2020163379A1
(en)
|
2019-02-05 |
2020-08-13 |
Emendobio Inc. |
Crispr compositions and methods for promoting gene editing of ribosomal protein s19 (rps19) gene
|
CN112805026A
(zh)
|
2019-02-06 |
2021-05-14 |
桑格摩生物治疗股份有限公司 |
用于治疗i型黏多糖贮积症的方法
|
US20220154157A1
(en)
|
2019-02-06 |
2022-05-19 |
Emendobio Inc. |
New engineered high fidelity cas9
|
EP3938506A4
(en)
|
2019-02-26 |
2022-12-14 |
Twist Bioscience Corporation |
VARIANT NUCLEIC ACID LIBRARIES FOR OPTIMIZATION OF ANTIBODIES
|
CN113766930A
(zh)
|
2019-02-26 |
2021-12-07 |
特韦斯特生物科学公司 |
Glp1受体的变异核酸文库
|
US20200316116A1
(en)
|
2019-04-02 |
2020-10-08 |
Sangamo Therapeutics, Inc. |
Method for the treatment of beta-thalassemia
|
BR112021021075A2
(pt)
|
2019-05-01 |
2021-12-14 |
Editas Medicine Inc |
Células que expressam um receptor recombinante de um locus de tgfbr2 modificado, polinucleotídeos relacionados e métodos
|
KR20220016474A
(ko)
|
2019-05-01 |
2022-02-09 |
주노 쎄러퓨티크스 인코퍼레이티드 |
변형된 cd247 유전자 자리로부터 키메라 수용체를 발현하는 세포, 관련 폴리뉴클레오타이드 및 방법
|
US11332738B2
(en)
|
2019-06-21 |
2022-05-17 |
Twist Bioscience Corporation |
Barcode-based nucleic acid sequence assembly
|
EP4034566A4
(en)
|
2019-09-23 |
2024-01-24 |
Twist Bioscience Corporation |
VARIANT NUCLEIC ACID LIBRARIES FOR CRTH2
|
JP2022553828A
(ja)
|
2019-11-01 |
2022-12-26 |
サンガモ セラピューティクス, インコーポレイテッド |
ゲノム操作のための組成物および方法
|
CA3161254A1
(en)
|
2019-12-16 |
2021-06-24 |
Katelijn D'HALLUIN |
Improved genome editing using paired nickases
|
US20230220405A1
(en)
|
2019-12-16 |
2023-07-13 |
BASF Agricultural Solutions Seed US LLC |
Precise introduction of dna or mutations into the genome of wheat
|
CN115803435A
(zh)
|
2020-05-06 |
2023-03-14 |
塞勒克提斯公司 |
用于在细胞基因组中靶向插入外源序列的方法
|
US20230279440A1
(en)
|
2020-05-06 |
2023-09-07 |
Cellectis S.A. |
Methods to genetically modify cells for delivery of therapeutic proteins
|
KR20230022868A
(ko)
|
2020-05-13 |
2023-02-16 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
|
JP2023531531A
(ja)
|
2020-06-26 |
2023-07-24 |
ジュノ セラピューティクス ゲーエムベーハー |
組換え受容体を条件付きで発現する操作されたt細胞、関連ポリヌクレオチド、および方法
|
US11976019B2
(en)
|
2020-07-16 |
2024-05-07 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
KR20230056669A
(ko)
|
2020-07-27 |
2023-04-27 |
안자리움 바이오사이언시스 아게 |
Dna 분자의 조성물, 이의 제조 방법 및 이의 사용 방법
|
WO2022098787A1
(en)
|
2020-11-04 |
2022-05-12 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
MX2023005665A
(es)
|
2020-11-16 |
2023-08-01 |
Pig Improvement Co Uk Ltd |
Animales resistentes a la influenza a que tienen genes de anp32 editados.
|
EP4314280A1
(en)
|
2021-03-22 |
2024-02-07 |
Juno Therapeutics, Inc. |
Method to assess potency of viral vector particles
|
AU2022260111A1
(en)
|
2021-04-20 |
2023-11-30 |
Anjarium Biosciences Ag |
Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
|
TW202328442A
(zh)
|
2021-09-10 |
2023-07-16 |
美商安進公司 |
平臺宿主對igf—培養基之適應
|
WO2023077012A1
(en)
|
2021-10-27 |
2023-05-04 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for expressing factor ix for hemophilia b therapy
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
WO2023105244A1
(en)
|
2021-12-10 |
2023-06-15 |
Pig Improvement Company Uk Limited |
Editing tmprss2/4 for disease resistance in livestock
|
WO2023135273A2
(en)
|
2022-01-14 |
2023-07-20 |
Anjarium Biosciences Ag |
Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
|
IL314482A
(en)
|
2022-02-02 |
2024-09-01 |
Regeneron Pharma |
Anti-TFR:GAA and anti-CD63:GAA insertions for the treatment of Pompe disease
|
WO2023212677A2
(en)
|
2022-04-29 |
2023-11-02 |
Regeneron Pharmaceuticals, Inc. |
Identification of tissue-specific extragenic safe harbors for gene therapy approaches
|
WO2024013514A2
(en)
|
2022-07-15 |
2024-01-18 |
Pig Improvement Company Uk Limited |
Gene edited livestock animals having coronavirus resistance
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
WO2024161021A1
(en)
|
2023-02-03 |
2024-08-08 |
Juno Therapeutics Gmbh |
Methods for non-viral manufacturing of engineered immune cells
|
WO2024170778A1
(en)
|
2023-02-17 |
2024-08-22 |
Anjarium Biosciences Ag |
Methods of making dna molecules and compositions and uses thereof
|
WO2024181446A1
(ja)
*
|
2023-02-28 |
2024-09-06 |
住友化学株式会社 |
ニッキング酵素、dna編集システム、標的dnaの編集方法、及び標的dnaが編集された細胞の製造方法
|